Universal Cells Inc. is a revolutionary therapeutic genome editing company that uses nuclease-free technology to develop “off-the-shelf” stem cell products that are universally compatible. While an early-stage company, this novel approach to stem cell engineering has the potential completely alter stem cell therapeutics.
In major news released today, Universal Cells announced that it has entered into an agreement with HEALIOS K.K. in Japan, the world’s leading company producing induced pluripotent stem cell (iPSC) therapeutics. Together, Universal Cells and Healios will create “Universal Donor iPSCs by editing the genes required for antigen presentation.”
To learn more, read the full press release issued by Universal Cells, printed with permission from Gregory Block, VP Business Development at Universal Cells. [Read more…]